Synergistic immunomodulatory effect in macrophages mediated by magnetic nanoparticles modified with miRNAs

Lafuente-Gómez, Nuria; Wang, Shiqi; Fontana, Flavia; Dhanjani, Mónica; García-Soriano, David; Correia, Alexandra; Castellanos, Milagros; Diaz, Ciro Rodriguez; Salas, Gorka; Santos, Hélder A.; Somoza, Álvaro

doi:10.1039/d2nr01767a

Cited by 17 publications

(14 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More importantly, additional conjugation of CD47 onto nanoparticles has the potential to fortify nanoparticle platforms in various biomedical fields, [ 56 ] including metabolic analysis, [ 57 ] cancer therapy, [ 58,59 ] and cancer diagnosis. [ 60 ] This is because the presence of CD47 on the nanoparticles enables the maintenance of their concentration and extended circulation time in the bloodstream.…”

Section: Discussionmentioning

confidence: 99%

Extracorporeal Blood Treatment Using Functional Magnetic Nanoclusters Mitigates Organ Dysfunction of Sepsis in Swine

Park,

Kim

et al. 2023

Small Methods

View full text Add to dashboard Cite

Mitigating sepsis‐induced severe organ dysfunction with magnetic nanoparticles has shown remarkable advances in extracorporeal blood treatment. Nevertheless, treating large septic animals remains challenging due to insufficient magnetic separation at rapid blood flow rates (>6 L h−1) and limited incubation time in an extracorporeal circuit. Herein, superparamagnetic nanoclusters (SPNCs) coated with red blood cell (RBC) membranes are developed, which promptly capture and magnetically separate a wide range of pathogens at high blood flow rates in a swine sepsis model. The SPNCs exhibited an ultranarrow size distribution of clustered iron oxide nanocrystals and exceptionally high saturation magnetization (≈ 90 emu g−1) close to that of bulk magnetite. It is also revealed that CD47 on the RBCs allows the RBC‐SPNCs to remain at a consistent concentration in the blood by evading innate immunity. The uniform size distribution of the RBC‐SPNCs greatly enhances their effectiveness in eradicating various pathogenic materials in extracorporeal blood. The use of RBC‐SPNCs for extracorporeal treatment of swine infected with multidrug‐resistant E. coli is validated and found that severe bacteremic sepsis‐induced organ dysfunction is significantly mitigated after 12 h. The findings highlight the potential application of RBC‐SPNCs for extracorporeal therapy of severe sepsis in large animal models and potentially humans.

show abstract

Section: Discussionmentioning

confidence: 99%

Extracorporeal Blood Treatment Using Functional Magnetic Nanoclusters Mitigates Organ Dysfunction of Sepsis in Swine

Park,

Kim

et al. 2023

Small Methods

View full text Add to dashboard Cite

show abstract

“…For example, Nuria et al described a magnetic nanoparticle involved the preparation of three different coatings and corresponding NPs: dextran (D-MNP), carboxymethyldextran (CMD-MNP), and dimercaptosuccinic acid (DMSA-MNP), thus forming the respective nanoparticles (Figure 18a). 298 Within this innovative landscape, CMD-MNP nanoparticles loaded with miRNA155 and miRNA125b elicited a pro-inflammatory cascade in human macrophages, marked by the upregulation of CD80 as well as elevated levels of cytokines TNF-α and IL-6. This observation posits that the devised miRNA-delivery nanosystem, predicated on magnetic nanoparticles, holds significant promise as a cutting-edge immunotherapeutic modality.…”

Section: Magnetic Field-responsive Delivery Systemsmentioning

confidence: 99%

“…Many magnetic field-based RNA delivery strategies primarily use nanoassemblies with cationic polymers to adsorb nucleic acid, which can improve the RNA loading capacity and transfection efficiency. For example, Nuria et al described a magnetic nanoparticle involved the preparation of three different coatings and corresponding NPs: dextran (D-MNP), carboxymethyldextran (CMD-MNP), and dimer-captosuccinic acid (DMSA-MNP), thus forming the respective nanoparticles (Figure a) . Within this innovative landscape, CMD-MNP nanoparticles loaded with miRNA155 and miRNA125b elicited a pro-inflammatory cascade in human macrophages, marked by the upregulation of CD80 as well as elevated levels of cytokines TNF-α and IL-6.…”

Section: Chemical Modification On Rna Therapeutics In Recent Researchmentioning

confidence: 99%

See 1 more Smart Citation

Chemically Modified Platforms for Better RNA Therapeutics

Shi,

Zhen,

Zhang

et al. 2024

Chem. Rev.

View full text Add to dashboard Cite

RNA-based therapies have catalyzed a revolutionary transformation in the biomedical landscape, offering unprecedented potential in disease prevention and treatment. However, despite their remarkable achievements, these therapies encounter substantial challenges including low stability, susceptibility to degradation by nucleases, and a prominent negative charge, thereby hindering further development. Chemically modified platforms have emerged as a strategic innovation, focusing on precise alterations either on the RNA moieties or their associated delivery vectors. This comprehensive review delves into these platforms, underscoring their significance in augmenting the performance and translational prospects of RNA-based therapeutics. It encompasses an in-depth analysis of various chemically modified delivery platforms that have been instrumental in propelling RNA therapeutics toward clinical utility. Moreover, the review scrutinizes the rationale behind diverse chemical modification techniques aiming at optimizing the therapeutic efficacy of RNA molecules, thereby facilitating robust disease management. Recent empirical studies corroborating the efficacy enhancement of RNA therapeutics through chemical modifications are highlighted. Conclusively, we offer profound insights into the transformative impact of chemical modifications on RNA drugs and delineates prospective trajectories for their future development and clinical integration. CONTENTS1. Introduction 930 2. Current Status and Challenges of RNA Therapeutics in Clinics 933 2.1. Molecular Mechanisms and Clinical Research Progress of RNAs 934 2.1.1. ASO 934 2.1.2. siRNA 934 2.1.3. Aptamer 936 2.1.4. mRNA 936 2.1.5. RNA Therapeutics on the Cusp of Clinical Breakthroughs 938 2.2. Major Challenges of Current RNA Therapeutics in Clinics 940 2.

show abstract

“…Additionally, nanoparticle-based vaccines are generally easily recognized and internalized by APCs because these are specialized in phagocytosing foreign materials [ [12] , [13] , [14] , [15] , [16] ]. Magnetic nanoparticles (MNP) have been explored for cancer immunotherapy for their high biocompatibility, intrinsic adjuvant properties, and ease of surface modification for controlled drug release applications [ [17] , [18] , [19] , [20] ]. Moreover, they can be degraded and metabolized into ferritin that is incorporated into cellular metabolic routes, preventing any toxicity issues [ [21] , [22] , [23] ].…”

Section: Introductionmentioning

confidence: 99%

Multifunctional magnetic nanoparticles elicit anti-tumor immunity in a mouse melanoma model

Lafuente-Gómez,

de Lázaro,

Dhanjani

et al. 2023

Materials Today Bio

Self Cite

View full text Add to dashboard Cite

Synergistic immunomodulatory effect in macrophages mediated by magnetic nanoparticles modified with miRNAs

Abstract: The interactions of magnetic nanoparticles with blood components must be carefully assessed to select nanoparticles for biomedical applications. Remarkably, MNP's surface can be tuned to add and enhance immunomodulatory properties in macrophages.

Cited by 17 publications

References 69 publications

Extracorporeal Blood Treatment Using Functional Magnetic Nanoclusters Mitigates Organ Dysfunction of Sepsis in Swine

Extracorporeal Blood Treatment Using Functional Magnetic Nanoclusters Mitigates Organ Dysfunction of Sepsis in Swine

Chemically Modified Platforms for Better RNA Therapeutics

Multifunctional magnetic nanoparticles elicit anti-tumor immunity in a mouse melanoma model

Contact Info

Product

Resources

About